U.S. markets open in 5 hours 27 minutes
  • S&P Futures

    4,263.50
    +8.75 (+0.21%)
     
  • Dow Futures

    34,431.00
    +50.00 (+0.15%)
     
  • Nasdaq Futures

    14,151.75
    +27.00 (+0.19%)
     
  • Russell 2000 Futures

    2,327.10
    +3.50 (+0.15%)
     
  • Crude Oil

    71.25
    +0.37 (+0.52%)
     
  • Gold

    1,868.80
    +2.90 (+0.16%)
     
  • Silver

    27.84
    -0.20 (-0.71%)
     
  • EUR/USD

    1.2146
    +0.0024 (+0.19%)
     
  • 10-Yr Bond

    1.5010
    0.0000 (0.00%)
     
  • Vix

    16.30
    +0.65 (+4.15%)
     
  • GBP/USD

    1.4117
    +0.0009 (+0.06%)
     
  • USD/JPY

    110.0300
    -0.0310 (-0.03%)
     
  • BTC-USD

    40,406.60
    +308.59 (+0.77%)
     
  • CMC Crypto 200

    1,014.79
    +45.95 (+4.74%)
     
  • FTSE 100

    7,179.63
    +32.95 (+0.46%)
     
  • Nikkei 225

    29,441.30
    +279.50 (+0.96%)
     

What Type Of Returns Would CASI Pharmaceuticals'(NASDAQ:CASI) Shareholders Have Earned If They Purchased Their Shares Three Years Ago?

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

It's not possible to invest over long periods without making some bad investments. But really bad investments should be rare. So take a moment to sympathize with the long term shareholders of CASI Pharmaceuticals, Inc. (NASDAQ:CASI), who have seen the share price tank a massive 75% over a three year period. That'd be enough to cause even the strongest minds some disquiet. Furthermore, it's down 51% in about a quarter. That's not much fun for holders. We note that the company has reported results fairly recently; and the market is hardly delighted. You can check out the latest numbers in our company report.

Check out our latest analysis for CASI Pharmaceuticals

CASI Pharmaceuticals isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually expect strong revenue growth. Some companies are willing to postpone profitability to grow revenue faster, but in that case one does expect good top-line growth.

The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).

earnings-and-revenue-growth
earnings-and-revenue-growth

We like that insiders have been buying shares in the last twelve months. Having said that, most people consider earnings and revenue growth trends to be a more meaningful guide to the business. You can see what analysts are predicting for CASI Pharmaceuticals in this interactive graph of future profit estimates.

A Different Perspective

CASI Pharmaceuticals shareholders are down 7.2% for the year, but the market itself is up 58%. Even the share prices of good stocks drop sometimes, but we want to see improvements in the fundamental metrics of a business, before getting too interested. Longer term investors wouldn't be so upset, since they would have made 3%, each year, over five years. If the fundamental data continues to indicate long term sustainable growth, the current sell-off could be an opportunity worth considering. It's always interesting to track share price performance over the longer term. But to understand CASI Pharmaceuticals better, we need to consider many other factors. Take risks, for example - CASI Pharmaceuticals has 4 warning signs (and 1 which is concerning) we think you should know about.

There are plenty of other companies that have insiders buying up shares. You probably do not want to miss this free list of growing companies that insiders are buying.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on US exchanges.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.